Can the Interim Fluorodeoxyglucose–Positron Emission Tomography Standardized Uptake Value Be Used to Determine the Need for Residual Mass Biopsy After Dose-Dense Immunochemotherapy for Advanced Diffuse Large B-Cell Lymphoma?
- 1 December 2010
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (34), e719-e720
- https://doi.org/10.1200/jco.2010.30.4394
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2010
- Interim18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand?Leukemia & Lymphoma, 2009
- Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of ChemotherapyJournal of Nuclear Medicine, 2009
- Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual AnalysisJournal of Nuclear Medicine, 2007
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- Positron-Emission Tomography and Assessment of Cancer TherapyThe New England Journal of Medicine, 2006
- Role of Positron Emission Tomography in LymphomaJournal of Clinical Oncology, 2005